JP2016521710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521710A5 JP2016521710A5 JP2016518012A JP2016518012A JP2016521710A5 JP 2016521710 A5 JP2016521710 A5 JP 2016521710A5 JP 2016518012 A JP2016518012 A JP 2016518012A JP 2016518012 A JP2016518012 A JP 2016518012A JP 2016521710 A5 JP2016521710 A5 JP 2016521710A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- cycloalkyl
- alkyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 48
- 125000001072 heteroaryl group Chemical group 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000011379 keloid formation Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CCC(C)N(C12CC1)C=NC2=*c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1*C(C*2N=C(C=CC=C3)C3=N2)(C(C=CC(C)C2)=C2F)OC1 Chemical compound CCC(C)N(C12CC1)C=NC2=*c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1*C(C*2N=C(C=CC=C3)C3=N2)(C(C=CC(C)C2)=C2F)OC1 0.000 description 9
- QNDXGVVJTUSTQB-UHFFFAOYSA-N CC(C(C)O)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CCC2N=CC=NC2)(c(ccc(Cl)c2)c2Cl)OC1 Chemical compound CC(C(C)O)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CCC2N=CC=NC2)(c(ccc(Cl)c2)c2Cl)OC1 QNDXGVVJTUSTQB-UHFFFAOYSA-N 0.000 description 1
- YPAYQJKUDLACIV-UHFFFAOYSA-N CCC(C)C(C1=O)N=CN1c(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2[IH]C2)c2)c2Cl)OC1 Chemical compound CCC(C)C(C1=O)N=CN1c(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2[IH]C2)c2)c2Cl)OC1 YPAYQJKUDLACIV-UHFFFAOYSA-N 0.000 description 1
- ASWUIZFNLVGPAW-YDEBFSDOSA-N CCC(C)N(C(C1)=O)N=C[C@H]1[C@H](C)c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CC2N=CC=NC2)(c(ccc(I)c2)c2Cl)OC1 Chemical compound CCC(C)N(C(C1)=O)N=C[C@H]1[C@H](C)c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CC2N=CC=NC2)(c(ccc(I)c2)c2Cl)OC1 ASWUIZFNLVGPAW-YDEBFSDOSA-N 0.000 description 1
- QDWFDNZETTWLSB-UHFFFAOYSA-N CCC(C)N(C1=C=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2c(cccc3)c3nc2)(c(ccc(Cl)c2)c2Cl)OC1 Chemical compound CCC(C)N(C1=C=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2c(cccc3)c3nc2)(c(ccc(Cl)c2)c2Cl)OC1 QDWFDNZETTWLSB-UHFFFAOYSA-N 0.000 description 1
- ZOGDGJPWNNBENZ-LTYZHWICSA-N CCCN(CC/C=C(\C)/c(cc1)ccc1OCC1OC(Cc2ccncc2)(c(ccc(Cl)c2)c2Cl)OC1)c1ccc(CC(C=NN2C(C)CC)=CC2=O)cc1 Chemical compound CCCN(CC/C=C(\C)/c(cc1)ccc1OCC1OC(Cc2ccncc2)(c(ccc(Cl)c2)c2Cl)OC1)c1ccc(CC(C=NN2C(C)CC)=CC2=O)cc1 ZOGDGJPWNNBENZ-LTYZHWICSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832768P | 2013-06-07 | 2013-06-07 | |
| US61/832,768 | 2013-06-07 | ||
| PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521710A JP2016521710A (ja) | 2016-07-25 |
| JP2016521710A5 true JP2016521710A5 (enExample) | 2017-01-26 |
| JP6414831B2 JP6414831B2 (ja) | 2018-10-31 |
Family
ID=52008597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518012A Active JP6414831B2 (ja) | 2013-06-07 | 2014-06-05 | 繊維症の小分子阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9663499B2 (enExample) |
| EP (2) | EP3626242B1 (enExample) |
| JP (1) | JP6414831B2 (enExample) |
| KR (1) | KR102240329B1 (enExample) |
| CN (1) | CN105392364B (enExample) |
| AU (1) | AU2014274830B2 (enExample) |
| BR (1) | BR112015030203A2 (enExample) |
| CA (1) | CA2913634C (enExample) |
| CL (1) | CL2015003569A1 (enExample) |
| DK (1) | DK3003038T3 (enExample) |
| EA (1) | EA201592157A1 (enExample) |
| ES (2) | ES2991873T3 (enExample) |
| HK (1) | HK1221606A1 (enExample) |
| MX (1) | MX2015016783A (enExample) |
| PE (1) | PE20160523A1 (enExample) |
| PL (1) | PL3003038T3 (enExample) |
| PT (1) | PT3003038T (enExample) |
| SG (1) | SG11201510011VA (enExample) |
| TN (1) | TN2015000519A1 (enExample) |
| WO (1) | WO2014197738A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| HK1221606A1 (zh) | 2013-06-07 | 2017-06-09 | 加州生物医学研究所 | 纤维化的小分子抑制剂 |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| JP6706023B2 (ja) * | 2014-12-10 | 2020-06-03 | ザ・スクリップス・リサーチ・インスティテュート | 線維症の小分子阻害剤 |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| EP3445385A4 (en) * | 2016-04-18 | 2019-11-20 | The Trustees of Columbia University in the City of New York | THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
| CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
| CN112040950A (zh) * | 2018-03-19 | 2020-12-04 | 上海偕怡医药科技有限公司 | 治疗特发性肺纤维化的方法和组合物 |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12048686B2 (en) | 2018-10-14 | 2024-07-30 | The University Of Chicago | Compositions and methods for activating NRF2-dependent gene expression |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| JP2023520911A (ja) * | 2020-04-07 | 2023-05-22 | アマリン ファーマシューティカルズ アイルランド リミテッド | ウイルスによって引き起こされるウイルス感染及び／又は疾患の治療及び／又は予防を必要としている対象においてそれらを行う方法 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| CN1041425C (zh) | 1993-11-19 | 1998-12-30 | 国际壳牌研究有限公司 | 氧化稳定的聚酮聚合物组合物及其应用 |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5625064A (en) * | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CA2413878A1 (en) | 2000-06-20 | 2001-12-27 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CA2709203A1 (en) * | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| US20100092479A1 (en) | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110183948A1 (en) | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| WO2013036866A1 (en) * | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| HK1221606A1 (zh) | 2013-06-07 | 2017-06-09 | 加州生物医学研究所 | 纤维化的小分子抑制剂 |
| SI3004106T1 (en) | 2013-06-07 | 2018-03-30 | Rhizen Pharmaceuticals S.A. | Dual selective PI3 delta and gamma inhibitors |
-
2014
- 2014-06-05 HK HK16109962.7A patent/HK1221606A1/zh unknown
- 2014-06-05 EP EP19191562.8A patent/EP3626242B1/en active Active
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en not_active Ceased
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 ES ES19191562T patent/ES2991873T3/es active Active
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521710A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2016196492A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| JP2015514806A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| NZ610151A (en) | Salts and crystalline forms of an apoptosis-inducing agent | |
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2016525075A5 (enExample) | ||
| JP2011252024A5 (enExample) | ||
| JP2017537937A5 (enExample) | ||
| JP2017538769A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| JP2015514808A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2014520767A5 (enExample) | ||
| JP2013531074A5 (enExample) | ||
| JP2016512515A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2019532092A5 (enExample) |